Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's disease

This page shows the latest Parkinson's disease news and features for those working in and with pharma, biotech and healthcare.

Lilly partners with AC Immune on tau drug for Alzheimer’s

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm. Eli Lilly has had no luck when it comes to developing Alzheimer’s disease (AD) drugs, but it’s not giving up – spending ... Aggregation of tau into 'tangles' is however a feature of a number of

Latest news

More from news
Approximately 23 fully matching, plus 176 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • The dark side of direct-to-consumer genetic tests

    Instead,   they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

  • The power of the patient

    In this episode, we talk to Matt Eagles who was diagnosed with Parkinson's Disease aged just eight. ... He has also written a series of articles for Parkinson's UK in their Quarterly Journal.

  • Leading Edge expands their senior medical writing team

    of Oxford, where she studied the use of stem cells as an in-vitro model of Parkinson’s disease.

  • Top 7 Trends in Pharma Marketing for 2015

    Wearable tech will play an even more integral role in the collection of aggregated patient data to help identify disease trends, predict treatment outcomes and improve future diagnoses. What we anticipate ... are collaborating with 23andMe to analyse

  • How can pharma help doctors in treating neurological disorders?

    The large number of treatments that are now available to treat neurological disorders, such as multiple sclerosis (MS) and Parkinson’s disease, and the complex nature of these medications, are key

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics